BRPI0815135A2 - Derivados de azepina como inibidores de gama secretase. - Google Patents

Derivados de azepina como inibidores de gama secretase.

Info

Publication number
BRPI0815135A2
BRPI0815135A2 BRPI0815135-0A2A BRPI0815135A BRPI0815135A2 BR PI0815135 A2 BRPI0815135 A2 BR PI0815135A2 BR PI0815135 A BRPI0815135 A BR PI0815135A BR PI0815135 A2 BRPI0815135 A2 BR PI0815135A2
Authority
BR
Brazil
Prior art keywords
secretase
azepine derivatives
inhibitors
range
range inhibitors
Prior art date
Application number
BRPI0815135-0A2A
Other languages
English (en)
Inventor
Melinda Joy Hope Miller
Warren Jaye Porter
Jon Kevin Reel
Almudena Rubio Esteban
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0815135A2 publication Critical patent/BRPI0815135A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0815135-0A2A 2007-08-14 2008-08-04 Derivados de azepina como inibidores de gama secretase. BRPI0815135A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0815135A2 true BRPI0815135A2 (pt) 2015-02-03

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815135-0A2A BRPI0815135A2 (pt) 2007-08-14 2008-08-04 Derivados de azepina como inibidores de gama secretase.

Country Status (11)

Country Link
US (1) US8188069B2 (pt)
EP (1) EP2178844A1 (pt)
JP (1) JP5385904B2 (pt)
KR (1) KR101136260B1 (pt)
CN (1) CN101778826B (pt)
AU (1) AU2008287124B2 (pt)
BR (1) BRPI0815135A2 (pt)
CA (1) CA2694209C (pt)
EA (1) EA017286B1 (pt)
MX (1) MX2010001754A (pt)
WO (1) WO2009023453A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2010060088A2 (en) 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
WO2013036679A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
WO2014047393A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
EP3458091B1 (en) 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
JP2006520396A (ja) * 2003-03-14 2006-09-07 アストラゼネカ・アクチエボラーグ 新規なラクタム及びその使用

Also Published As

Publication number Publication date
JP5385904B2 (ja) 2014-01-08
AU2008287124A1 (en) 2009-02-19
CN101778826A (zh) 2010-07-14
EA201070278A1 (ru) 2010-06-30
JP2010536766A (ja) 2010-12-02
EA017286B1 (ru) 2012-11-30
MX2010001754A (es) 2010-05-14
CA2694209A1 (en) 2009-02-19
CA2694209C (en) 2013-09-17
US20100197660A1 (en) 2010-08-05
US8188069B2 (en) 2012-05-29
KR101136260B1 (ko) 2012-04-19
CN101778826B (zh) 2012-10-31
AU2008287124B2 (en) 2013-06-06
WO2009023453A1 (en) 2009-02-19
KR20100032924A (ko) 2010-03-26
EP2178844A1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
BRPI0814256A2 (pt) Inibidores de tetrahidropiranocromeno gama secretase
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI1008749A2 (pt) Derivados de benzodiazepina
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0812170A2 (pt) Moduladores de gama secretase
BRPI0817935A2 (pt) Derivados de biarila
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0813768A2 (pt) Derivados de benzazepina úteis como antagonistas de vasopressina
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.